The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).

Dr. Nicole Hoffmeister-Kraut, Minister of Economic Affairs, Labour and Tourism of Baden-Württemberg, together with Freiburg’s Mayor Martin Horn, gives the go-ahead for the construction project on the Georges-Köhler-Allee.

Proteins have characteristic amino acid sequences, the analysis of which is fundamental for research and medicine. These can be decoded; however, so-called protein sequencing is expensive and time-consuming. A large-scale research project led by Prof. Dr. Jan Behrends from the Institute of Physiology at the University of Freiburg now aims to establish a new technology for protein sequencing using nanopores, which will be rapid and cost-effective.

HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value

The German Federal Ministry of Education and Research (BMBF) is currently funding a project at the Department of Oral and Maxillofacial Surgery at Heidelberg University Hospital with around 1.2 million euros. The aim is to use 3D printing technology to produce individualized implants directly in the clinic, thus enabling faster, more efficient and more precise patient-specific care. To this end, the UKHD is working with an industrial partner.

The Collaborative Research Centre (CRC) 1550 “Molecular Circuits of Heart Disease” at Heidelberg University is entering its second funding period. The German Research Foundation (DFG) has approved approximately EUR 17.4 million in funding for the next four years. The spokesperson is Johannes Backs, Professor of Experimental Cardiology at the Heidelberg Faculty of Medicine.

Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.

Researchers have developed a new method that greatly improves the accuracy of brain-state classification with functional near-infrared spectroscopy (fNIRS). The brain-imaging technique fNIRS allows researchers to measure neural activity: Active brain cells need more oxygen, so variations in blood flow and oxygen saturation indicate which brain regions are at work. fNIRS detects these changes safely and without invasive procedures.

NVision announced a $55 million Series B led by Abbott and unveiled PIQC, a new quantum computing platform built on its molecular quantum technology.

NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure.

Dossier - 12/03/2012

Regenerative medicine makes use of patients own resources

Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.

The German Research Foundation (DFG) has announced the first pivotal decisions for the "Clusters of Excellence" funding line as part of the Excellence Strategy of the German federal and state governments. The University of Stuttgart has been given the green light for two new cluster initiatives.

Viral cancer therapy - 26/10/2022

Therapeutic viruses against tumours and metastases

Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

Innovative Therapies - 20/08/2020

Labor Dr. Merk is fully committed to viral therapies

Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.

Worldwide, almost one third of women of childbearing age suffer from bacterial vaginosis. Such a disorder of the vaginal flora can cause urogenital infections, abscesses on the ovaries or fallopian tubes or premature births. As part of a BW Sprint project, the DITF have laid the basis for the development of a panty liner that supports the health of the vaginal environment and can prevent bacterial vaginosis.

This month marks the launch of an outstanding project integrating artificial intelligence (AI) and neuromedicine – the Hertie Institute for Artificial Intelligence in Brain Health (Hertie AI). Founded on February 1 at the Medical Faculty of the University of Tübingen, it will be the first institute in Germany to research the prevention and early diagnosis of diseases of the nervous system using artificial intelligence methods.

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

Developing replacement methods for animal testing is the main goal of the 3R network. One of three new 3R centres in Baden-Württemberg was launched at Ulm University at the beginning of the year and has now officially started work with a kick-off event. The abbreviation 3R stands for "Replace, Reduce, Refine", i.e. replace and reduce animal testing and improve the conditions for unavoidable animal experiments.

In the current selection round, the German Research Foundation (DFG) has granted funding for two new Collaborative Research Centres at the University of Konstanz. Over the next four years, the research teams will be working intensively on trigger signals in biological cells as well as on "silence" and "noise" in human speech.

ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.

This year Furtwangen University (HFU) is launching the “HFU Skills4MedTec” project to further enhance its profile as a leading authority in medical technology and to develop targeted scientific training courses for specialists and managers in the industry.

Effective July 1, the Hahn-Schickard Association for Applied Research e.V. will spin off its operational business and transfer it to the newly founded Hahn-Schickard gGmbH. This nonprofit company has assumed the universal legal succession of the association and has been entered in the commercial register of the Stuttgart District Court. It is legally represented by its managing director, Dr. Karl-Peter Fritz.

The University of Freiburg is strengthening its European collaboration in the field of Artificial Intelligence by having been accepted into the Virtual Centre of Excellence of the European AI initiative ELIAS. The Freiburg researchers contribute their expertise to the European network in areas including machine learning, computer vision, robot learning, automated reasoning, intelligent systems and neurotechnologies, as well as responsible AI.

Tumors of the pancreas seldom cause symptoms in their early stages. This means that in many cases, they are not diagnosed until late, when the chances of successful treatment are poor. A new non-invasive diagnostic method designed by Fraunhofer researchers is set to make it possible to detect this aggressive form of cancer early on with high accuracy, significantly improving the prognosis for treatment.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

Germany has the most active market, Southern Europe wants more variety, and people in Poland find dairy substitutes too expensive, according to a recent study by the University of Hohenheim.

More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.

Heidelberg Technology Park - 05/05/2020

Start-up support for life sciences companies

How can scientists turn their know-how into marketable products and services and thereby provide society with real added value? In addition to solid financing, start-up companies need a suitable infrastructure and a dense network of partners for exchanging expertise to help them get off to a good start when it comes to setting up a business. The Heidelberg Technology Park offers company founders in the life sciences exactly these success factors.

NeuroQ project - 26/07/2023

Quantum sensors for exoskeletons: can quantum physics beat paralysis?

Could people suddenly be able to move again decades after being paralysed? State-of-the-art quantum sensors integrated in exoskeletons could make this possible. Technology being developed as part of the BMBF-funded NeuroQ beacon project by researchers from organisations including the Fraunhofer IAF, the Charité in Berlin and the University of Stuttgart might achieve even more: besides facilitating movement, it could also help cure paralysis.

CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demon­strated relevance in glioblastoma. A first data readout is expected in the second half of 2024.

Soft robots, robot systems made of soft materials, open up new perspectives for medical technology and industry. Jun.-Prof. Dr. Aniket Pal from the University of Stuttgart is conducting research into viscoelastic materials that have the potential to embed intelligent functions in soft robots. He is receiving 1.5 million euros in funding for this research as part of the Emmy Noether Program. The funding period began on September 1, 2025.

Sixteen leading life science and IT companies, all-new livestreamed presentations, and an informative career panel made for a successful EMBL Industry Day in its second year

Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020

A rapid pyrogen test: the human immune system as model

Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

The committee of the Joint Science Conference of the federal government and federal states in its meeting cleared the way for the application submitted by ZEW Mannheim for a research programme focusing on the implications of the digital transformation for the analysis and the design of digital health care markets. This paves the way for an expansion of the Institute's activities by establishing an independent health economics research unit.

Start-up Cerebri GmbH - 05/08/2024

Comprehensive EEG supply thanks to telemedicine

Fewer and fewer patients are getting timely access to electroencephalograms, as the process of measuring brain activity and interpreting the results requires specific expertise. Cerebri GmbH, a newly established Tübingen-based company, aims to address this issue by offering user-friendly EEG caps and providing rapid, location-independent and top-tier diagnostics by experts.

Innovations in the field of endoscopy - 08/06/2020

Gastroscopies with pill cameras

A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

Workplace of the future - 10/08/2021

Intelligent body support system for surgery staff

Operating room staff often spend hours in strenuous postures, which has a significant impact on concentration and quality of work. While operating room equipment is increasingly networked, state-of-the-art medical technology, conditions for operating room staff trail way behind. The start-up company Hellstern medical offers an effective solution for serious pain, fatigue and incorrect interventions.

High-resolution microscopy technology bypassing the diffraction limit - 26/10/2023

From micro- to nanoscope

It has long been impossible to distinguish objects closer than 200 nanometres using light microscopes. However, novel devices developed by a company called abberior Instruments GmbH, which use technology developed by Nobel Prize winner Prof. Dr. Stefan Hell and his teams in Heidelberg and Göttingen, are now able to bypass this resolution limit and provide detailed insights into living cells in the lower nanometre range.

Vicinity Bio: Optimisation of cancer diagnostics - 27/11/2024

Comprehensive histological diagnostics through high-dimensional imaging and artificial intelligence

Microscopic examination of tissue samples is essential, particularly in tumour diagnostics. The Tübingen-based company Vicinity Bio leverages cutting-edge imaging technologies combined with machine learning to generate comprehensive datasets of individual cells from tissue sections. This approach not only helps identify more targeted therapies but also enhances our understanding of cellular functions and processes within tissues and tumours.

Scientists from the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center (DKFZ) have developed an AI model that assesses the long-term individual risk for more than 1,000 diseases. The model, which was trained and tested using anonymized medical data from the UK and Denmark, can predict health events over a period of more than a decade.

Hummingbird Diagnostics GmbH, a pioneer in harnessing blood-based small RNAs for early disease detection and characterization, today announced the publication of a new study in Nature Communications Medicine introducing an Oxford Nanopore Technologies (ONT)-based method for detecting small RNA modifications in blood.

In a study, a team of researchers show that groups of magnetic microrobots can generate fluidic forces strong enough to rotate objects in different directions without touching them. These microrobot swarms can turn gear systems, rotate objects much larger than the robots themselves, assemble structures on their own, and even pull in or push away many small objects. The work was now published in Science Advances.

Genome duplication probably gave biodiversity a decisive evolutionary boost. A Chinese-German research team led by Axel Meyer from the University of Konstanz has now investigated the early phases of the process known as re-diploidization. The results show that the fusion of chromosome sets is asynchronous.

Microfluidics in medical technology - 24/03/2021

Ultra-compact: valves with shape memory actuators

Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.